WA
UTHR icon

Waddell & Associates’s United Therapeutics UTHR Stock Holding History

Waddell & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$488K Buy
900
+25
+3% +$14.1K 0.02% 276
2026
Q1 		$519K Sell
875
-36
-4% -$17.9K 0.03% 229
2025
Q4 		$444K Buy
+911
New +$424K 0.03% 200

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Waddell & Associates's UTHR Position: Q2 2026 in Review

Waddell & Associates increased its United Therapeutics (UTHR) stake by 2.9% in Q2 2026, buying an estimated $14.1K and bringing the position to 900 shares worth $488K. The position accounts for 0.02% of the portfolio, ranked #276.

Waddell & Associates first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $519K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Waddell & Associates held 900 shares of United Therapeutics worth $488K as of Q2 2026.
  • Waddell & Associates bought 25 United Therapeutics shares in Q2 2026, an estimated $14.1K.
  • United Therapeutics made up 0.02% of Waddell & Associates's portfolio in Q2 2026, its #276 holding.
  • Waddell & Associates first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Waddell & Associates's United Therapeutics position peaked at $519K in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.